These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17472416)

  • 1. Guidelines for submitting adverse event reports for publication.
    Kelly WN; Arellano FM; Barnes J; Bergman U; Edwards RI; Fernandez AM; Freedman SB; Goldsmith DI; Huang KA; Jones JK; McLeay R; Moore N; Stather RH; Trenque T; Troutman WG; van Puijenbroek E; Williams F; Wise RP; ;
    Drug Saf; 2007; 30(5):367-73. PubMed ID: 17472416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for submitting adverse event reports for publication.
    Kelly WN; Arellano FM; Barnes J; Bergman U; Edwards IR; Fernandez AM; Freedman SB; Goldsmith DI; Huang K; Jones JK; McLeay R; Moore N; Stather RH; Trenque T; Troutman WG; van Puijenbroek E; Williams F; Wise RP; ;
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):581-7. PubMed ID: 17471601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for submitting adverse event reports for publication.
    Kelly W; Arellano F; Barnes J; Bergman U; Edwards R; Fernandez A; Freedman S; Goldsmith D; Huang K; Jones J; McLeay R; Moore N; Stather R; Trenque T; Troutman W; van Puijenbroek E; Williams F; Wise R; ;
    Therapie; 2009; 64(4):289-94. PubMed ID: 19804709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database.
    Impicciatore P; Mucci M
    Drug Saf; 2010 Sep; 33(9):765-73. PubMed ID: 20701409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
    Aronson JK
    Drug Saf; 2008; 31(4):355-6; author reply 356-7. PubMed ID: 18366246
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mandatory pharmacovigilance.
    Maksymowych WP
    CMAJ; 2003 Mar; 168(6):672; discussion 672-3. PubMed ID: 12642413
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
    Harinstein L; Kalra D; Kortepeter CM; Muñoz MA; Wu E; Dal Pan GJ
    Drug Saf; 2019 May; 42(5):649-655. PubMed ID: 30569267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern and quality of scientific communications on drug safety produced by a regional pharmacovigilance center in Nepal.
    Palaian S; Ibrahim MI; Mishra P
    Pharm Pract (Granada); 2010 Jul; 8(3):179-86. PubMed ID: 25126138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of the spanish pharmacovigilance system recommendations on the publication of cases of adverse drug reaction].
    Esteban Calvo C; Ibáñez Ruiz C; Salgueiro Vázquez E; Manso Rodríguez G
    Aten Primaria; 2008 Nov; 40(11):555-8. PubMed ID: 19055896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact Factors and Prediction of Popular Topics in a Journal.
    Nielsen MB; Seitz K
    Ultraschall Med; 2016 Aug; 37(4):343-5. PubMed ID: 27490462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quality of published adverse drug event reports.
    Kelly WN
    Ann Pharmacother; 2003 Dec; 37(12):1774-8. PubMed ID: 14632590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endotoxin-like reactions with intravenous gentamicin: results from pharmacovigilance tools under investigation.
    Hauben M; Reich L
    Infect Control Hosp Epidemiol; 2005 Apr; 26(4):391-4. PubMed ID: 15865275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
    Moore TJ; Furberg CD; Mattison DR; Cohen MR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.
    Perrio M; Voss S; Shakir SA
    Drug Saf; 2007; 30(4):333-46. PubMed ID: 17408310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.